Trial Profile
An Observational study to characterize pharmacokinetics and pharmacogenetics of Rilpivirine in HIV infected patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2016
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Pharmacokinetics
- 21 Nov 2016 New trial record
- 31 Oct 2016 Results published in the Antimicrobial Agents and Chemotherapy